Učitavanje...

FAILURE OF HYPOMETHYLATING AGENT-BASED THERAPY IN MYELODYSPLASTIC SYNDROMES

Hypomethylating agents such as 5-azacytidine or decitabine have been a major breakthrough in the treatment of patients with myelodysplastic syndromes (MDS). They have been shown to improve transfusion requirements and change the natural history of the disease. However, with increasing cumulative cli...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kadia, Tapan M., Jabbour, Elias, Kantarjian, Hagop
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4098768/
https://ncbi.nlm.nih.gov/pubmed/21943675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.seminoncol.2011.04.011
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!